Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.60 |
| ▸ | DRD4 | P21917 | 5/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7792010 | 0.88 | DRD2 (0.58) | DRD2DRD4DRD3 | |
| SCHEMBL7783722 | 0.88 | DRD2 (0.58) | DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7789479 | 0.84 | DRD2 (0.64) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL7788928 | 0.80 | MAPT (0.52) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL7783724 | 0.76 | DRD2 (0.54) | DRD2DRD4DRD3 | |
| Ci-1007 SCHEMBL7783725 | 0.76 | DRD2 (1.00) | DRD2DRD4DRD3 | |
| SCHEMBL9379218 | 0.74 | DRD2 (0.80) | DRD2DRD4DRD3 | |
| SCHEMBL9379222 | 0.74 | DRD2 (0.80) | DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7783715 | 0.74 | DRD2 (0.78) | DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7783712 | 0.74 | DRD2 (0.78) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0613465-B1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | claimed |
| JP-3193718-B2 | — | — | 2001-07-30 | — | — | JP | claimed |
| EP-0613465-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-09-07 | — | — | EP | claimed |
| EP-0545095-A1 | 1,3-Substituted cycloalkenes and cycloalkanes as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1993-06-09 | — | — | EP | claimed |
| WO-1993010092-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
| EP-0613465-B1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-0613465-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-09-07 | — | — | EP | disclosed |
| EP-0545095-A1 | 1,3-Substituted cycloalkenes and cycloalkanes as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1993010092-A1 | 1,3-SUBSTITUTED CYCLOALKENES AND CYCLOALKANES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |